Johnson & Johnson achieves 5.9% sales growth in third quarter and raises earnings guidance
Published · Reading time 2 min
اقرأ بالعربيةJohnson & Johnson announced 5.9% sales growth in the third quarter 2026, adjusted earnings per share of $2.59, and raised its full-year earnings per share guidance to $11.10.
What this means
Johnson & Johnson continued its growth in the third quarter driven by approximately 6% sales increase, reflecting strong demand for its products. The reported earnings per share of $0.09 is lower due to exceptional accounting items, but adjusted earnings per share of $2.59 provides a clearer picture of operational performance. The company's raise in full-year earnings guidance signals management confidence in sustained positive performance, particularly following new regulatory approvals for important medical products during the quarter.
Details
Johnson & Johnson announced its financial results for the third quarter of 2026, according to the company's filing with regulatory authorities. Sales recorded reported growth of 5.9%, operational growth excluding currency fluctuations of 6.0%, while adjusted operational growth reached 6.1%. Diluted earnings per share (EPS) for the third quarter reached $0.09, while adjusted earnings per share came to $2.59. The significant difference between the two figures is typically attributable to exceptional items such as restructuring charges or legal settlements that do not reflect daily operational performance. On guidance, the company raised its adjusted earnings per share guidance for full-year 2026 by $0.06 to reach $11.10 at the midpoint, representing 2.9% growth. The company also expects full-year reported sales of $101.2 billion at the midpoint, with 7.4% growth. During the third quarter, the company received approval from the U.S. Food and Drug Administration (FDA) to market its OTTAVA robotic surgical system in the United States. Additionally, IMAAVY (nipocalimab-aahu) received FDA approval as the first treatment for warm autoimmune hemolytic anemia (wAIHA), according to the company's filing.
Sources and verification
We matched every figure against its official source, and the article passed a second, independent review before publication. This content is produced with automated tools under editorial checks.
Information to help you understand, not investment advice